<p>A candidate Covid-19 vaccine known as EpiVacCorona, Russia's second to be registered, proved "100% effective" in early-stage trials, Russian consumer health watchdog Rospotrebnadzor has told local media.</p>.<p>The data, based on Phase I and II trials, were released before the start of a larger Phase III trial which would normally involve thousands of participants and a placebo group as a comparison.</p>.<p>"The effectiveness of the vaccine is made up of its immunological effectiveness and preventative effectiveness," the TASS news agency reported, citing Rospotrebnadzor.</p>.<p>"According to results of the first and second phases of clinical trials, the immunological effectiveness of the EpiVacCorona vaccine is 100%."</p>.<p>Read: <a href="https://www.deccanherald.com/international/global-gaps-in-covid-19-vaccine-access-cause-concern-940376.html">Global gaps in Covid-19 vaccine access cause concern</a></p>.<p>The Phase I and II studies tested the safety, side-effects and immunogenicity of the potential vaccine in 100 people aged 18-60, according to the state trials register.</p>.<p>Typically early-stage vaccine tests on humans are based on blood readings showing an immune response in participants who have not been exposed to the virus, while the results of larger late-stage trials are based on actual infections suffered by participants in their normal lives.</p>.<p>Russia began testing EpiVacCorona, which is being developed by Siberia's Vector Institute, in November.</p>.<p>Earlier that month, Moscow said its other approved vaccine, Sputnik V, was 92% effective at protecting people from Covid-19 based on interim results.</p>.<p>Read: <a href="https://www.deccanherald.com/national/india-to-start-covid-19-vaccine-exports-as-soon-as-jan-20-940837.html">India to start Covid-19 vaccine exports as soon as Jan 20</a></p>.<p>Russia has said it can inoculate 60% of its population against Covid-19 this year, and although the Sputnik V vaccine has been readily available in Moscow, the rollout across the country has been slow.</p>.<p>Russian President Vladimir Putin has ordered mass vaccinations to start this week.</p>.<p>EpiVacCorona will be used in mass vaccinations from March, Deputy Prime Minister Tatiana Golikova told the Interfax news agency.</p>.<p>Russia has reported 3,612,800 coronavirus cases, the world's fourth-highest total. Its death toll from the virus stands at 66,623.</p>
<p>A candidate Covid-19 vaccine known as EpiVacCorona, Russia's second to be registered, proved "100% effective" in early-stage trials, Russian consumer health watchdog Rospotrebnadzor has told local media.</p>.<p>The data, based on Phase I and II trials, were released before the start of a larger Phase III trial which would normally involve thousands of participants and a placebo group as a comparison.</p>.<p>"The effectiveness of the vaccine is made up of its immunological effectiveness and preventative effectiveness," the TASS news agency reported, citing Rospotrebnadzor.</p>.<p>"According to results of the first and second phases of clinical trials, the immunological effectiveness of the EpiVacCorona vaccine is 100%."</p>.<p>Read: <a href="https://www.deccanherald.com/international/global-gaps-in-covid-19-vaccine-access-cause-concern-940376.html">Global gaps in Covid-19 vaccine access cause concern</a></p>.<p>The Phase I and II studies tested the safety, side-effects and immunogenicity of the potential vaccine in 100 people aged 18-60, according to the state trials register.</p>.<p>Typically early-stage vaccine tests on humans are based on blood readings showing an immune response in participants who have not been exposed to the virus, while the results of larger late-stage trials are based on actual infections suffered by participants in their normal lives.</p>.<p>Russia began testing EpiVacCorona, which is being developed by Siberia's Vector Institute, in November.</p>.<p>Earlier that month, Moscow said its other approved vaccine, Sputnik V, was 92% effective at protecting people from Covid-19 based on interim results.</p>.<p>Read: <a href="https://www.deccanherald.com/national/india-to-start-covid-19-vaccine-exports-as-soon-as-jan-20-940837.html">India to start Covid-19 vaccine exports as soon as Jan 20</a></p>.<p>Russia has said it can inoculate 60% of its population against Covid-19 this year, and although the Sputnik V vaccine has been readily available in Moscow, the rollout across the country has been slow.</p>.<p>Russian President Vladimir Putin has ordered mass vaccinations to start this week.</p>.<p>EpiVacCorona will be used in mass vaccinations from March, Deputy Prime Minister Tatiana Golikova told the Interfax news agency.</p>.<p>Russia has reported 3,612,800 coronavirus cases, the world's fourth-highest total. Its death toll from the virus stands at 66,623.</p>